

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NUTRI.018RAAPPLICATION NO.
09/912,472INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Mark F. McCartyFILING DATE
July 24, 2001GROUP
1614

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
h	5,336,672	08/09/94	Southern, Jr. et al.			
h	5,470,846	11/29/95	Sandyk			
h	5,496,827	03/05/96	Patrick			
h	5,597,585	01/28/97	Williams et al.			
h	5,635,535	06/03/97	Wagstaff			

RECEIVED
DEC 19 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
h	WO 91/11117	08/08/91	PCT WO				
h	WO 96/25939	08/29/96	PCT WO				

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

h	Anderson, R.A. (1997) Nutritional factors influencing the glucose/insulin system: Chromium. Journal of the American College of Nutrition. 16(5):404-410.
h	Cefalu et al. (1997) The effect of chromium supplementation on carbohydrate metabolism and body fat distribution. Diabetes. 46:55a.
h	Maebashi et al. (1993) Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin dependent diabetes mellitus. J. Clin. Biochem. Nutr. 14:211-218.
h	McCarty (1991) The case for supplemental chromium and a survey of clinical studies with chromium picolinate. Journal of Applied Nutrition. 43(1):58-66.
h	Ravina et al. (1995) Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. The Journal of Trace Elements in Experimental Medicine. 8:183-190.

S:\DOCS\MKD\MKD-3356.DOC\120902

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.